title: Effects of sustained low-level muscarinic agonism in rats.
abstract: Sustained, low level muscarinic activity was induced in rats by feeding the muscarinic agonist and experimental drug candidate CI-969 at 50, 100 and 200 mg/kg body weight/day for 4 wk. Except for urine staining, clinical signs typical of acute high-dose exposure to muscarinic agonists were not observed. A dose-related suppression of body weight gain approached 60% at the high dose, but no significant effects on haematology or clinical chemical parameters were observed after 4 wk of exposure. Corneal opacities with histopathological features including neovascularization, acanthosis and stromal proliferation were observed in a dose-related fashion in both sexes at 100 and 200 mg/kg/day. Hypertrophy of the Harderian and lacrimal glands also occurred, probably as an adaptive response to sustained muscarinic activity. Lacrimal gland concentrations of the muscarinic agonist were in the range of pmol/mg tissue and therefore significant direct exposure of cornea to the compound through the tears was discounted. The presence of corneal muscarinic receptors was investigated to determine whether opacities could be related to direct, receptor-mediated events in the cornea; however, no specific binding of the muscarinic receptor radioligand [3H]quinuclidylbenzilate was detected. Because muscarinic agonist-induced opacities can be inhibited by scopolamine, the apparent lack of muscarinic receptors in the cornea indicates that the opacities are not a direct effect, but are instead secondary to muscarinic events at another site. To our knowledge, this is the first report of corneal opacities induced by a muscarinic agonist.
authors.affiliation: Department of Pathology and Experimental Toxicology, Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, Ann Arbor, MI 48105.
authors.forename: L A
authors.initials: LA
authors.lastname: Dethloff
authors.forename: P
authors.initials: P
authors.lastname: Wilga
authors.forename: M
authors.initials: M
authors.lastname: Seefeld
authors.forename: H
authors.initials: H
authors.lastname: Ulloa
authors.forename: K
authors.initials: K
authors.lastname: Hawkins
authors.forename: J
authors.initials: J
authors.lastname: Petrere
mesh_terms: D000818:Animals; D001835:Body Weight / Q000187:drug effects; D003315:Cornea / Q000187:drug effects; D005260:Female; D008297:Male; D010277:Parasympathomimetics / Q000097:blood / Q000633:toxicity*; D011725:Pyridines / Q000097:blood / Q000633:toxicity*; D011813:Quinuclidinyl Benzilate / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D011976:Receptors, Muscarinic / Q000187:drug effects* / Q000378:metabolism
chemical_list: D010277:Parasympathomimetics; D011725:Pyridines; D011976:Receptors, Muscarinic; C089013:CI 969; D011813:Quinuclidinyl Benzilate